Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Immunotherapy
• Thoracic Surgery

Background:

• Standard treatments for localized and locally advanced non-small cell lung cancer (NSCLC) include surgery and chemoradiation.
• While potentially curative, these therapies have high relapse rates, necessitating improved treatment strategies.
• Immune checkpoint inhibitors (ICIs) have transformed advanced NSCLC care, prompting investigation into their use in earlier disease stages.

Purpose of the Study:

• To review current evidence and ongoing research on the role of ICIs in non-metastatic NSCLC.
• To evaluate the efficacy of neoadjuvant and adjuvant ICI therapies in resectable NSCLC.
• To define the potential impact of immunotherapy on reducing disease recurrence in early-stage NSCLC.

Main Methods:

• Review of recently reported clinical trials and ongoing studies.
• Analysis of data on neoadjuvant and adjuvant ICI treatment regimens.
• Evaluation of pathologic response rates, resection margins, and survival outcomes.

Main Results:

• Neoadjuvant ICI treatment demonstrates significant pathologic response rates and facilitates R0 resections.
• Adjuvant ICI therapy following chemotherapy improves disease-free survival in resectable NSCLC.
• Consolidation durvalumab is established for inoperable, locally advanced NSCLC.

Conclusions:

• ICIs are increasingly important in the management of non-metastatic NSCLC.
• Neoadjuvant and adjuvant ICI strategies offer promising improvements in outcomes for early-stage NSCLC.
• Further research is crucial to establish optimal immunotherapy protocols for non-metastatic NSCLC.